Hiroaki Hata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiroaki Hata has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Kohei Fujita
National Hospital Organization Kyoto Medical Center
4 shared publications Motomi Shiono
Department of Cardiac Surgery, Nihon University School of Medicine, 30-1 Oyaguchikamimachi, Itabashi-ku, Tokyo, 173-8610, Japan
4 shared publications- Hiroki Nakanishi
Lipidome Lab Co., Ltd., Akita 010-0825, Japan
3 shared publications Masashi Saji
Department of Emergency and Critical Care Medicine, National Hospital Organization, Kyoto Medical Center
3 shared publications- Masato Narita
Department of Surgery, -Kobe City Medical Center General Hospital, Kobe, Japan
3 shared publications - Osamu Kanai
Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
3 shared publications
Latest Publications
- 2 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (9) , 103026
Device-Associated Infection Surveillance in Japan: 2025 Annual Report of the Japanese Society for Infection Prevention and Control
- 2 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (9) , 103026
Device-Associated Infection Surveillance in Japan: 2025 Annual Report of the Japanese Society for Infection Prevention and Control
- 18 December 2023
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (1) , 137-141
Clinical features of pneumothorax associated with COVID-19: A retrospective analysis of two centres
- 18 December 2023
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (1) , 137-141
Clinical features of pneumothorax associated with COVID-19: A retrospective analysis of two centres
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1268. A retrospective observational study to evaluate the efficacy of antimicrobial time-out for optimizing the duration of antimicrobial administration in emergency abdominal surgery patients
Appropriate use of antibiotics is important for the prevention of antimicrobial-resistant organisms. However, prolonged administration of broad-spectrum antimicrobial agents is frequently used in surgery, especially in emergency surgery with infection. The low rate of the appropriate use of antimicrobial agents is regarded as a worldwide problem. In order to promote the proper use of antimicrobials, our department has administered daily antimicrobial time-outs to surgical patients as part of the Antimicrobial Stewardship Program since January 2018. This study investigates whether the Antimicrobial Time-out has led to appropriate use of antibiotics. Patients aged 18 years and older who underwent emergency abdominal surgery in our department from May 2017 to August 2018 were included. Pre- and postoperative clinical information was extracted from the medical records. 56 and 66 patients were treated before and after the introduction of antimicrobial time-out, respectively. The mean duration of antimicrobial use was 3.8 and 3.3 days before and after the introduction of antibiotic time-out. No significant difference was observed, but a 13.7% decrease was observed (P=0.51). Limiting the analysis to patients who received a minimum of two days of antimicrobial therapy, treated patients were 23 and 27, and the mean duration of antimicrobial use was 7.8 and 6.6 days(P=0.38) before and after the introduction of antibiotic time-out, respectively. There were also no significant differences in the incidence of complications (Clavien-Dindo classification Grade II or higher) (28.6% vs. 25.8%, P=0.73) or length of hospital stay (17.2 vs. 14.0 days, P=0.38). Antibiotic time-out in surgical practice may contribute to a reduction in antimicrobial use without increasing complication rates or length of hospital stay. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1268. A retrospective observational study to evaluate the efficacy of antimicrobial time-out for optimizing the duration of antimicrobial administration in emergency abdominal surgery patients
Appropriate use of antibiotics is important for the prevention of antimicrobial-resistant organisms. However, prolonged administration of broad-spectrum antimicrobial agents is frequently used in surgery, especially in emergency surgery with infection. The low rate of the appropriate use of antimicrobial agents is regarded as a worldwide problem. In order to promote the proper use of antimicrobials, our department has administered daily antimicrobial time-outs to surgical patients as part of the Antimicrobial Stewardship Program since January 2018. This study investigates whether the Antimicrobial Time-out has led to appropriate use of antibiotics. Patients aged 18 years and older who underwent emergency abdominal surgery in our department from May 2017 to August 2018 were included. Pre- and postoperative clinical information was extracted from the medical records. 56 and 66 patients were treated before and after the introduction of antimicrobial time-out, respectively. The mean duration of antimicrobial use was 3.8 and 3.3 days before and after the introduction of antibiotic time-out. No significant difference was observed, but a 13.7% decrease was observed (P=0.51). Limiting the analysis to patients who received a minimum of two days of antimicrobial therapy, treated patients were 23 and 27, and the mean duration of antimicrobial use was 7.8 and 6.6 days(P=0.38) before and after the introduction of antibiotic time-out, respectively. There were also no significant differences in the incidence of complications (Clavien-Dindo classification Grade II or higher) (28.6% vs. 25.8%, P=0.73) or length of hospital stay (17.2 vs. 14.0 days, P=0.38). Antibiotic time-out in surgical practice may contribute to a reduction in antimicrobial use without increasing complication rates or length of hospital stay. All Authors: No reported disclosures
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
525. Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood. We conducted a single-centre retrospective study and assessed the outcome of patients with COVID-19 treated with molnupiravir according to the following criteria: (A) discontinuation rate of molnupiravir; (B) type, frequency, and severity of adverse events; (C) all-cause mortality within 30 days of the diagnosis of COVID-19. Forty-seven patients (46.1%) were aged ≥ 80 years (older patients) and 55 (53.9%) were aged < 80 years (younger patients). There were no significant differences in coexisting diseases and history of vaccination for COVID-19 between older and younger patients. Older patients were significantly more likely to have moderate disease (moderate 1 and 2) according to the Japanese Ministry of Health, Labour and Welfare classification than younger patients. During treatment, 8.5% of older patients and 1.8% of younger patients stopped taking molnupiravir, but the difference was not significant. Adverse events were observed in 39/102 (38.2%) patients. The most common adverse events were diarrhoea (9.8%), exacerbation of coexisting diseases (6.9%), bone marrow suppression (6.9%), liver dysfunction (5.9%), and loss of appetite (4.9%). Most adverse events were minor, ranging from grades 1 to 3. The all-cause mortality rate was 10.8%, and no molnupiravir-related deaths were observed. Molnupiravir treatment is acceptable and safe in older patients with COVID-19 aged ≥ 80 years. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access525. Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood. We conducted a single-centre retrospective study and assessed the outcome of patients with COVID-19 treated with molnupiravir according to the following criteria: (A) discontinuation rate of molnupiravir; (B) type, frequency, and severity of adverse events; (C) all-cause mortality within 30 days of the diagnosis of COVID-19. Forty-seven patients (46.1%) were aged ≥ 80 years (older patients) and 55 (53.9%) were aged < 80 years (younger patients). There were no significant differences in coexisting diseases and history of vaccination for COVID-19 between older and younger patients. Older patients were significantly more likely to have moderate disease (moderate 1 and 2) according to the Japanese Ministry of Health, Labour and Welfare classification than younger patients. During treatment, 8.5% of older patients and 1.8% of younger patients stopped taking molnupiravir, but the difference was not significant. Adverse events were observed in 39/102 (38.2%) patients. The most common adverse events were diarrhoea (9.8%), exacerbation of coexisting diseases (6.9%), bone marrow suppression (6.9%), liver dysfunction (5.9%), and loss of appetite (4.9%). Most adverse events were minor, ranging from grades 1 to 3. The all-cause mortality rate was 10.8%, and no molnupiravir-related deaths were observed. Molnupiravir treatment is acceptable and safe in older patients with COVID-19 aged ≥ 80 years. All Authors: No reported disclosures
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1467. Effects Of Oral Antibiotic Prophylaxis For Surgical Site Infections In Colorectal Surgery: Insights From Real World Data
Surgical site infection (SSI) after colorectal surgery is a significant burden on healthcare costs and patient quality of life. Preventive strategies are very important to working on this problem. In a multicenter randomized controlled trial (RCT) published in Annals of Surgery(2016;263:1085-1091), we reported the efficacy of oral antimicrobial prophylaxis in preventing SSI before colorectal surgery. Since the end of the RCT in 2012, we have applied this prophylaxis in our clinical practice and have experienced a large number of cases. Here, we report the incidence of SSIs when this prophylactic measure is applied in real-world clinical practice. We retrospectively evaluated the incidence of SSI in 1192 patients who underwent elective laparoscopic colorectal resection for colorectal tumors between January 2013 and June 2022. We excluded 24 patients who were unable to receive oral prophylaxis. Antimicrobial prophylaxis consisted of oral kanamycin (1 g) and metronidazole (750 mg) twice on the day before surgery and intravenous cefmetazole (1 g) just before and every 3 hours during surgery. The diagnosis of SSI follows the CDC/NHSN definition. Our study included 647 males and 545 females, with a mean age of 69.3 years (IQR 63-77) and BMI of 22.6 kg/m2 (IQR 20.2-24.7). The incidence of SSI in all surgical cases was 61/1192 (5.1%; 95% CI 4.0-6.5). The incidence of SSIs in colon surgery was 16/769 (2.1%; 95% CI 1.3-3.4), and in rectal surgery, 45/400 (11.3%; 95% CI 8.5-14.7). The incidence of Clostridioides difficile colitis, which is regarded as a side effect of oral antimicrobial agents, was low at 6/1192 cases (0.5%; 05%CI 0.2-1.1). In our previous RCT, the incidence of SSI was 21/289 (7.26%) in patients treated with oral antibiotics. In a subanalysis of this trial published in the International Journal of Colorectal Disease(2016;31:1775-1784), the incidence of SSI was 9/188 (4.8%) in colon surgery and 13/103 (13%) in rectal surgery. The incidence of SSIs in the present data was similar to or lower than the incidence of SSIs in well-conditioned patients selected in the RCT. Our results suggest that preoperative oral antibiotic prophylaxis in colorectal surgery is an effective method to reduce SSIs in a wide variety of patients in real-world clinical practice. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1467. Effects Of Oral Antibiotic Prophylaxis For Surgical Site Infections In Colorectal Surgery: Insights From Real World Data
Surgical site infection (SSI) after colorectal surgery is a significant burden on healthcare costs and patient quality of life. Preventive strategies are very important to working on this problem. In a multicenter randomized controlled trial (RCT) published in Annals of Surgery(2016;263:1085-1091), we reported the efficacy of oral antimicrobial prophylaxis in preventing SSI before colorectal surgery. Since the end of the RCT in 2012, we have applied this prophylaxis in our clinical practice and have experienced a large number of cases. Here, we report the incidence of SSIs when this prophylactic measure is applied in real-world clinical practice. We retrospectively evaluated the incidence of SSI in 1192 patients who underwent elective laparoscopic colorectal resection for colorectal tumors between January 2013 and June 2022. We excluded 24 patients who were unable to receive oral prophylaxis. Antimicrobial prophylaxis consisted of oral kanamycin (1 g) and metronidazole (750 mg) twice on the day before surgery and intravenous cefmetazole (1 g) just before and every 3 hours during surgery. The diagnosis of SSI follows the CDC/NHSN definition. Our study included 647 males and 545 females, with a mean age of 69.3 years (IQR 63-77) and BMI of 22.6 kg/m2 (IQR 20.2-24.7). The incidence of SSI in all surgical cases was 61/1192 (5.1%; 95% CI 4.0-6.5). The incidence of SSIs in colon surgery was 16/769 (2.1%; 95% CI 1.3-3.4), and in rectal surgery, 45/400 (11.3%; 95% CI 8.5-14.7). The incidence of Clostridioides difficile colitis, which is regarded as a side effect of oral antimicrobial agents, was low at 6/1192 cases (0.5%; 05%CI 0.2-1.1). In our previous RCT, the incidence of SSI was 21/289 (7.26%) in patients treated with oral antibiotics. In a subanalysis of this trial published in the International Journal of Colorectal Disease(2016;31:1775-1784), the incidence of SSI was 9/188 (4.8%) in colon surgery and 13/103 (13%) in rectal surgery. The incidence of SSIs in the present data was similar to or lower than the incidence of SSIs in well-conditioned patients selected in the RCT. Our results suggest that preoperative oral antibiotic prophylaxis in colorectal surgery is an effective method to reduce SSIs in a wide variety of patients in real-world clinical practice. All Authors: No reported disclosures
- Open Access
- 5 September 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (12) , 5770-5772
The “Plug folding” may be a pathogenesis in chronic postoperative inguinal pain following mesh plug repair
- 5 September 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (12) , 5770-5772
Open AccessThe “Plug folding” may be a pathogenesis in chronic postoperative inguinal pain following mesh plug repair
- Open Access
- 25 May 2023
- Published by Japanese Society of Environmental Infections in Japanese Journal of Infection Prevention and Control
- Vol. 38 (3) , 75-79
Safe and Effective Skin Antiseptics in Gastrointestinal Surgery
手術野の皮膚消毒は,ヨード系消毒薬・アルコール製剤・グルコン酸クロルヘキシジンが頻用される消毒薬であるが,新たな皮膚消毒薬であるオラネキシジンの有効性を検証したRCTが報告された.一方,消化器外科領域の術野消毒では粘膜を含んだ術野の消毒に対しては,多くの消毒薬が禁忌であることから,各薬剤の有効性と注意点を理解して選択をする必要がある.本稿では,消化器外科領域の術野消毒で頻用される薬剤について,適応や禁忌,注意点を解説するとともに,有効性に関する最近の研究結果をまとめる.
- 25 May 2023
- Published by Japanese Society of Environmental Infections in Japanese Journal of Infection Prevention and Control
- Vol. 38 (3) , 75-79
Open AccessSafe and Effective Skin Antiseptics in Gastrointestinal Surgery
手術野の皮膚消毒は,ヨード系消毒薬・アルコール製剤・グルコン酸クロルヘキシジンが頻用される消毒薬であるが,新たな皮膚消毒薬であるオラネキシジンの有効性を検証したRCTが報告された.一方,消化器外科領域の術野消毒では粘膜を含んだ術野の消毒に対しては,多くの消毒薬が禁忌であることから,各薬剤の有効性と注意点を理解して選択をする必要がある.本稿では,消化器外科領域の術野消毒で頻用される薬剤について,適応や禁忌,注意点を解説するとともに,有効性に関する最近の研究結果をまとめる.
- Open Access
- 25 September 2022
- Published by Japanese Society of Environmental Infections in Japanese Journal of Infection Prevention and Control
- Vol. 37 (5) , 158-163
Strategies for Surgical Practice during COVID-19 Epidemic
日本におけるCOVID-19患者は,2022年4月時点で780万人を超えており,治療中の患者や既感染の患者に手術治療を行う機会が増えている.COVID-19患者に手術を行う場合は,以下の順に適応を考えるのが良い.1.術後合併症が多いため感染から7週間経過以降に行う.2.医療者への感染リスクを減らすために感染から10日間経過以降に行う.3.代替治療も困難であれば十分に感染対策を講じて緊急手術を行う.また,COVID-19患者であっても腹腔鏡手術の適応を変える必要はないが,サージカルスモークについて理解しておくことは重要である.これらの推奨の背景を近年の報告をもとにまとめた.
- 25 September 2022
- Published by Japanese Society of Environmental Infections in Japanese Journal of Infection Prevention and Control
- Vol. 37 (5) , 158-163
Open AccessStrategies for Surgical Practice during COVID-19 Epidemic
日本におけるCOVID-19患者は,2022年4月時点で780万人を超えており,治療中の患者や既感染の患者に手術治療を行う機会が増えている.COVID-19患者に手術を行う場合は,以下の順に適応を考えるのが良い.1.術後合併症が多いため感染から7週間経過以降に行う.2.医療者への感染リスクを減らすために感染から10日間経過以降に行う.3.代替治療も困難であれば十分に感染対策を講じて緊急手術を行う.また,COVID-19患者であっても腹腔鏡手術の適応を変える必要はないが,サージカルスモークについて理解しておくことは重要である.これらの推奨の背景を近年の報告をもとにまとめた.
- Open Access
- 6 June 2020
- Published by Wiley in World Journal of Surgery
- Vol. 44 (10) , 3433-3440
Comparison of Postoperative Quality of Life among Three Different Reconstruction Methods After Proximal Gastrectomy: Insights From the PGSAS Study
Background Proximal gastrectomy (PG) has become an increasingly preferred procedure for early cancer in the upper third of the stomach, owing to reportedly superior quality of life (QOL) after PG when compared with total gastrectomy. However, various methods of reconstruction have currently been proposed. We compared the postoperative QOL among the three different reconstruction methods after PG using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45) questionnaire. Methods Post Gastrectomy Syndrome Assessment Study (PGSAS), a nationwide multi-institutional survey, was conducted to evaluate QOL using the PGSAS-45 among various types of gastrectomy. Of the 2,368 eligible data from the PGSAS survey, data from 193 patients who underwent PG were retrieved and used in the current study. The PGSAS-45 consists of 45 items including 22 original gastrectomy specific items in addition to the SF-8 and GSRS. These were consolidated into 19 main outcome measures pertaining postgastrectomy symptoms, amount of food ingested, quality of ingestion, work, and level of satisfaction for daily work, and the three reconstruction methods (n = 193; 115 esophago-gastrostomy [PGEG], 34 jejunal interposition [PGJI], and 44 jejunal pouch interposition [PGJPI]) were compared using PGSAS-45. Results Size of the remnant stomach was significantly larger in PGEG, and significantly smaller in PGJI and PGJPI (P < 0.05). There was no difference in other patient background factors among the groups. EGJPI tended to be superior to PGEG in several of the 19 main outcome with marginal significance (P = 0.047–0.076). Conclusion PGJPI appears to be the most favorable of the three reconstruction methods after PG especially when the size of remnant stomach is rather small. Trial registration number UMIN-CTR #000002116 entitled as “A study to observe correlation between resection and reconstruction procedures employed for gastric neoplasms and development of postgastrectomy syndrome”
- 6 June 2020
- Published by Wiley in World Journal of Surgery
- Vol. 44 (10) , 3433-3440
Open AccessComparison of Postoperative Quality of Life among Three Different Reconstruction Methods After Proximal Gastrectomy: Insights From the PGSAS Study
Background Proximal gastrectomy (PG) has become an increasingly preferred procedure for early cancer in the upper third of the stomach, owing to reportedly superior quality of life (QOL) after PG when compared with total gastrectomy. However, various methods of reconstruction have currently been proposed. We compared the postoperative QOL among the three different reconstruction methods after PG using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45) questionnaire. Methods Post Gastrectomy Syndrome Assessment Study (PGSAS), a nationwide multi-institutional survey, was conducted to evaluate QOL using the PGSAS-45 among various types of gastrectomy. Of the 2,368 eligible data from the PGSAS survey, data from 193 patients who underwent PG were retrieved and used in the current study. The PGSAS-45 consists of 45 items including 22 original gastrectomy specific items in addition to the SF-8 and GSRS. These were consolidated into 19 main outcome measures pertaining postgastrectomy symptoms, amount of food ingested, quality of ingestion, work, and level of satisfaction for daily work, and the three reconstruction methods (n = 193; 115 esophago-gastrostomy [PGEG], 34 jejunal interposition [PGJI], and 44 jejunal pouch interposition [PGJPI]) were compared using PGSAS-45. Results Size of the remnant stomach was significantly larger in PGEG, and significantly smaller in PGJI and PGJPI (P < 0.05). There was no difference in other patient background factors among the groups. EGJPI tended to be superior to PGEG in several of the 19 main outcome with marginal significance (P = 0.047–0.076). Conclusion PGJPI appears to be the most favorable of the three reconstruction methods after PG especially when the size of remnant stomach is rather small. Trial registration number UMIN-CTR #000002116 entitled as “A study to observe correlation between resection and reconstruction procedures employed for gastric neoplasms and development of postgastrectomy syndrome”